HSANZ Free Communications 2: Myeloma
Tracks
HSANZ
| Monday, October 19, 2026 |
| 8:30 AM - 10:00 AM |
Speaker
Dr Su Li
Associate Chief Physician
Liquan Hospital / Gobroad Medical Institute of Hematology / Shanghai Center
Phase 1 study of SL0349, a bispecific nanobody based BCMA/GPRC5D CAR-T,in relapsed or refractory multiple myeloma
8:30 AM - 8:45 AM
Dr Georgia McCaughan
Haematologist
St Vincent's Hospital
Presence of end organ damage at commencement of second line therapy significantly impacts outcomes in Multiple Myeloma: An Australia and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR) Analysis
8:45 AM - 9:00 AM
Dr Daniel Wong
Haematologist
The Alfred Hospital
Circulating plasma MYC/BCL2 RNA co-expression in newly diagnosed multiple myeloma identifies patients with a higher risk of early progression
9:00 AM - 9:15 AM
Ms Belinda Maher
Research Assistant
Monash University
Exploiting Glucocorticoid-Induced Leucine Zipper (GILZ) to deliver the anti-myeloma effects of steroids without metabolic toxicities
9:15 AM - 9:30 AM
Dr Jesse Zhang
Registrar
Health New Zealand
Ethnic disparities in cytogenetic characteristics at diagnosis and survival of multiple myeloma patients within the Auckland region
9:30 AM - 9:45 AM
Prof P Joy Ho
Clinical Professor Haematology
Royal Prince Alfred Hospital
Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma
9:45 AM - 10:00 AM
